Indivior PLC announced its full-year 2026 financial guidance with total net revenue expected in the range of $1,125 million to $1,195 million.
The company anticipates total SUBLOCADE net revenue to be between $905 million and $945 million.
Non-GAAP operating expenses are projected to fall within the range of $430 million to $450 million.
Adjusted EBITDA is expected to be in the range of $535 million to $575 million.
Financial Guidance Overview
Indivior forecasts substantial revenue growth and margin expansion for 2026, driven by increased dispense units and a simplified operating model.
Business Transformation
The company successfully completed Phase I of its Indivior Action Agenda, resulting in significant organization simplification.
Incorporation Change
Indivior secured shareholder approval to shift its domicile from the U.K. to the U.S. to establish a new parent company, Indivior Pharmaceuticals, Inc.
Legacy DOJ Matter Resolution
The company settled its legacy U.S. Department of Justice matter by fully paying off the outstanding $295 million obligation.
- The financial guidance reflects a strategic shift towards growth and efficiency, setting clear targets for revenue and expense management.
- Indivior's focus on accelerating SUBLOCADE dispense unit growth and margin expansion indicates a proactive approach to driving financial performance.
Indivior's financial outlook for 2026 showcases a strong trajectory with revenue growth, margin expansion, and pivotal business developments. The company's proactive strategies and successful past initiatives position it favorably for the year ahead.